XNASSPRY
Market cap1.09bUSD
Jan 10, Last price
11.24USD
1D
-1.66%
1Q
-22.59%
IPO
-61.77%
Name
Silverback Therapeutics Inc
Chart & Performance
P/E
—
P/S
36,412.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.56%
Rev. gr., 5y
%
Revenues
30k
-97.72%
Net income
-54m
L+59.95%
CFO
-59m
L+47.88%
Earnings
Mar 19, 2025
Profile
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 30 -97.72% | 1,316 -76.10% | ||||
Cost of revenue | 67,623 | 54,152 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (67,593) | (52,836) | ||||
NOPBT Margin | ||||||
Operating Taxes | (694) | |||||
Tax Rate | ||||||
NOPAT | (67,593) | (52,142) | ||||
Net income | (54,365) 59.95% | (33,988) 67.90% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,899 | 570 | ||||
BB yield | -1.32% | -0.17% | ||||
| Debt | ||||||
Debt current | 474 | 230 | ||||
Long-term debt | 311 | 732 | ||||
Deferred revenue | 2,854 | |||||
Other long-term liabilities | 2,854 | |||||
Net debt | (227,575) | (273,419) | ||||
| Cash flow | ||||||
Cash from operating activities | (59,266) | (40,078) | ||||
CAPEX | (175) | (199) | ||||
Cash from investing activities | (87,180) | (199) | ||||
Cash from financing activities | 6,899 | 190,732 | ||||
FCF | (69,096) | (52,223) | ||||
| Balance | ||||||
Cash | 228,360 | 274,381 | ||||
Long term investments | ||||||
Excess cash | 228,358 | 274,315 | ||||
Stockholders' equity | (131,244) | 204,913 | ||||
Invested Capital | 362,515 | 73,988 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 95,215 | 39,956 | ||||
Price | 5.48 -35.76% | 8.53 28.08% | ||||
Market cap | 521,780 53.09% | 340,825 77.25% | ||||
EV | 294,205 | 348,841 | ||||
EBITDA | (67,520) | (52,517) | ||||
EV/EBITDA | ||||||
Interest | 834 | |||||
Interest/NOPBT | ||||||